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lamotrigine and topiramate as adjunctive therapy in the treat-
ment of LGS from a UK NHS perspective was assessed.
METHODS: A semi-Markov model with individual patient
simulation was developed to estimate the costs and clinical ben-
eﬁts of the newer antiepileptic drugs over a 3 year time horizon.
The outcome measure is the percentage of successfully treated
patients, with success deﬁned as50% reduction in frequency of
drop attacks. In the absence of head-to-head clinical trials, indi-
rect comparisons were made among the alternative therapies
using placebo as the common comparator. Health states applied
in the model were >75% reduction in seizure frequency, 50%–
75% reduction, <50% reduction and death. Transition prob-
abilities were derived from patient level trial data on ruﬁnamide
and published clinical trials for the comparators. Estimates for
resource use were derived from interviews with 5 practicing
paediatric epileptologists, to which published UK unit costs were
applied. Results of 10,000 Monte Carlo simulations were boot-
strapped to conduct probabilistic sensitivity analysis. RESULTS:
Over 3 years 11.3% of ruﬁnamide patients were treated success-
fully compared to 7.2% and 5.2% with topiramate and lamot-
rigine respectively. Total discounted costs of treatments were
respectively £50,985, £50,730 and £50,975 with a highly right-
skewed distribution. Mean incremental cost-effectiveness ratios
(ICER) for ruﬁnamide were £6,215 (90%CI: dominant–
£40,000) and £172 (dominant -£19,100) per 1% increase in
success rate versus topiramate and lamotrigine respectively. At
£13,000 per 1% increase in successfully treated patients over 3
years ruﬁnamide is has the highest probability of being cost-
effective. Shorter time horizons and higher hospitalisation rates
improved the cost-effectiveness of ruﬁnamide. CONCLUSION:
Ruﬁnamide is a cost-effective therapy compared to topiramate
and lamotrigine as adjunctive therapy in achieving greater than
50% reduction in frequency of drop attacks in LGS.
PND11
COMPARATIVE ANALYSIS OF MULTIPLE SCLEROSIS
COST-EFFECTIVENESS MODELS: FOCUS ONTHE UNITED
STATES MANAGED CARE PERSPECTIVE
Papshev D1, Bennett R2,AL-Sabbagh A2
1RXWORX, Inc,Yardley, PA, USA, 2EMD Serono, Inc, Rockland, MA,
USA
OBJECTIVES: To assess the scientiﬁc literature for studies evalu-
ating comparative economic value of the ﬁve disease modifying
drugs (DMDs) approved in the United States (U.S.) for the
management of relapsing forms of multiple sclerosis (MS).
METHODS: A comprehensive search of the MEDLINE data-
base, as well as the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) and Academy of Managed
Care Pharmacy (AMCP) meeting proceedings was conducted to
identify cost effectiveness (CE) analysis studies published or pre-
sented from 2004 through May 2007. Studies were critically
reviewed with regard to evaluated comparators, primary end-
points, measures of relapse reduction, perspective, timeframe,
and cost of therapy. RESULTS: The two identiﬁed CE analyses
both utilized cost per relapse avoided as the primary endpoint,
but the results varied signiﬁcantly in terms of CE ratios and
relative DMD rankings. The primary determinant of these varia-
tions was the methodology used to calculate relapse reduction
from the data reported in randomized placebo-controlled trials.
While the same clinical trials were employed by both models, the
number of avoided relapses was based on absolute reduction in
the case of Goldberg et al and on relative reduction in the case of
Chiao et al, and the models used different assumptions with
respect to timeframe, treatment adherence, monitoring costs,
contractual discounts, and member co-payments. Due to the
limitations inherent to the relative event reduction methodology,
the model developed by Chiao et al was highly sensitive to the
variation in the average relapse rate prior to treatment. CON-
CLUSION: The choice of methodology used to calculate thera-
peutic impact on relapse reduction can signiﬁcantly inﬂuence the
outcome of CE analyses. Considering signiﬁcant heterogeneity in
baseline disease severity among clinical trials in MS, use of abso-
lute reduction in relapse rate may be more appropriate as it more
accurately reﬂects the net clinical beneﬁt.
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OBJECTIVES: The EVidence of Interferon Dose-response Euro-
pean North American Comparative Efﬁcacy (EVIDENCE) trial
concluded administering subcutaneous (SC) IFNb1a 44 micro-
grams three times per week was more effective in improving the
proportion with relapsing form of multiple sclerosis (RFMS)
remaining relapse-free than intramuscular (IM) 30 micrograms
weekly after 24 and 48 weeks. This analysis utilized discrete
event simulation (DES) to model the potential longer-term clini-
cal and economic implications of this trial. METHODS: This
DES predicts the course of RFMS, reads in actual patient proﬁles
from the trial and creates two hypothetical cohorts—one receives
SC IFNb1a and the other IM. Patients may suffer relapses with
short- and long-term impact on costs and disability, develop new
T2 lesions, discontinue treatment, progress to secondary progres-
sive MS (SPMS) or die. Risk equations were derived from speciﬁc
analyses of trial data for relapse and supplemented with pub-
lished studies for SPMS and death. Direct medical costs to US
payers obtained from literature and databases were reported in
2006 USD and discounted at 3%. Extensive sensitivity analyses
were conducted. RESULTS: Based on 100 replications of 1000
patient pairs over four years, SC administration was predicted to
allow more patients to avoid a relapse (216 vs. 147). Total mean
costs per patient were $79,154 with SC vs. $73,820 with IM, a
net increase of $5335. SC IFNb1a was estimated to give a mean
of 0.50 relapses prevented, and 23 relapse-free days gained per
patient, yielding incremental cost effectiveness ratios of $10,616
per relapse prevented and $229 per relapse-free day gained.
Sensitivity analyses revealed that the result was most sensitive to
the cost of treatment, criteria for response, and treatment dura-
tion before assessing response. CONCLUSION: SC IFNb1a is
predicted to improve health outcomes over four years for a cost
that would seem an acceptable trade off.
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OBJECTIVES: To assess the cost-effectiveness of using a
lidocaine 5% medicated plaster in place of gabapentin (1800 mg/
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day; 1200 mg/day with add-in-medication) and pregabalin
(PG; 300 mg/day and 600 mg/day; 300 mg/day with add-in-
medication) for the treatment of post-herpetic neuralgia (PHN)
from the perspective of the German Sickness Funds. METHODS:
The costs and beneﬁts of gabapentin, PG and the lidocaine
plaster were calculated using a Markov model taking a six-
month time horizon. Transition probabilities were mainly based
on clinical trials identiﬁed through a systematic review. Missing
data, data on resource utilization and add-in/switch medication
were obtained from a Delphi panel. Cost data were taken from
ofﬁcial price lists. A modiﬁed TWIST (time without symptoms)
analysis was conducted to calculate the cost per additional
month with sufﬁcient pain relief and no intolerable side-effects.
RESULTS: Treatment with the lidocaine plaster costs a total of
€937 per patient, compared with €728 for generic gabapentin,
€875 for PG300 mg and dominated PG600 mg. Patients treated
with the lidocaine plaster spent an average of 4.06 months
(67.7% of the total treatment period) with adequate pain relief
and no intolerable side-effects, compared with 2.72 months
(45.3% of the total treatment period) for gabapentin, 3.02
months (50.3% of the total treatment period) for PG300 mg
and 3.22 months (53.7% of the total treatment period) for
PG600 mg. Lidocaine plaster therefore costs €156 per additional
month with sufﬁcient pain relief and no side-effects relative to
gabapentin, €60 relative to PG300 mg. The lidocaine plaster was
dominant over PG600 mg. Scenario analyses and extensive one-
way sensitivity analyses on all parameters including the time
horizon conﬁrmed the robustness of the results. CONCLU-
SIONS: Patients receiving the lidocaine 5% plaster for PHN
spend more time with sufﬁcient pain relief and no intolerable
side-effects than those treated with gabapentin or pregabalin.
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OBJECTIVES: To assess the cost-effectiveness of pregabalin
(PGB) and other add-on antiepileptic medicines over standard
therapy (ST) in patients with refractory partial epilepsy (RPE)
from the societal perspective in Finland. METHODS: A dynamic
simulation model was used to estimate outcomes and costs of a
hypothetical cohort of 1000 RPE patients over 1 year. Pregabalin
(PGB 300 mg/d) was compared to clinically and commercially
competitors: gabapentin (GBP 1800 mg/d), lamotrigine (LTG
300 mg/d), levetiracetam (LEV 2000 mg/d) and topiramate (TOP
200 mg/d). Number of seizure-free days (SFD) was used as an
outcome measure. Local costs of RPE medicines (excluding VAT)
and a specialist visit per a medicine switch were employed. Costs
per a SFD were calculated. To account for uncertainty around the
model estimates, the model was run for 50 samples. One-way
sensitivity analysis (PGB 600 mg/d, TOP 400 mg/d or employ-
ment of generic GBP price) was conducted. RESULTS: In com-
parison to ST, PGB (300 mg/d) yielded an average of additional
40 SFDs per a patient during a year. Incremental cost for PGB
was 29€ per a SFD (95%CI 23–36€). Corresponding estimate for
PGB (600 mg/d) was 44€ per a SFD whereas it varied 43–86€
among the comparators. At the dose of 600 mg/d, the PGB
incremental cost per a SFD was similar to GBP, but still lower
than among other comparators. CONCLUSION: Principal ﬁnd-
ings from the model suggest that PGB (300 mg/d) showed to be
a cost-effective add-on treatment for RPE patients in Finland
compared to ST. The incremental cost of PGB (300 mg/d) per a
SFD was lower than those of GBP, LTG and LEV with their
typical doses. One-way sensitivity analyses indicated that the
results were robust to plausible variations in the essential model
parameters, namely daily dose of PGB and TOP and price of
GBP.
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OBJECTIVES: To model the incremental cost-utility of Exelon
Patch versus best supportive care (BSC) in the management of
Alzheimer’s disease (AD), from the perspective of the UK NHS.
METHODS: The incremental costs and Quality Adjusted Life
Years (QALYs) associated with Exelon Patch treatment versus
BSC were calculated using an economic model. Changes in Mini
Mental State Examination (MMSE) scores over a 5-year period
were used as a measure of the progression of AD. The clinical
pathway was populated based on the results of the pivotal
IDEAL trial, with 12-month follow-up data from patients who
received Exelon Patch (n = 383) and 6-month follow-up data
from patients who received placebo (n = 282). The progression
of the disease was modelled beyond the study period using pub-
lished equations to predict the natural decline of MMSE in AD
patients. Costing variables included drugs, clinical monitoring
and institutionalisation. RESULTS: Exelon Patch was shown to
provide an incremental 0.1045 QALYs at an additional cost of
£1,363 per patient, giving a cost-utility of £13,042 per QALY
gained. One-way sensitivity analysis suggested that the main
determinants of cost-effectiveness were the probability of insti-
tutionalisation, the relationship between MMSE states and
quality of life, and the health economic perspective adopted.
When informal care costs were included in the analysis, Exelon
Patch was calculated to cost £634 per QALY gained. CONCLU-
SION: Exelon Patch has a superior cost-effectiveness proﬁle than
many treatments currently funded by the NHS. Further research
studies focusing on activities of daily living to demonstrate costs
and beneﬁts of treatment are warranted.
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OBJECTIVES: Evaluate the prevalence and costs of commonly
reported insomnia comorbidities. METHODS: A database of US
employees from 2001–2006 was used to identify subjects with
insomnia (based on the International Classiﬁcation of Diseases–9
[ICD-9] codes or prescription for a hypnotic agent) and control
employees (3:1) (matched by demographics, job information,
and geographic region). Direct medical costs (inﬂated to 2006
dollars) for each comorbid condition, based on ICD-9 codes
from the Agency for Health Research and Quality 261 Speciﬁc
Categories, were analyzed for the 12 months after insomnia
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